Logo Image

Authors

Denise Myshko, OncLive
Denise Myshko

Senior Editor, OncLive®
Denise Myshko is your editorial contact for the Oncology Business Management section of OncologyLive, as well as the corporate newsletters. She joined OncologyLive in March 2020. Before that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@onclive.com

Latest Article

No-Cost Counseling Can Address Psychosocial Needs of Patients With Cancer

Counseling, psychotherapy, and mental health services provide the opportunity to develop coping skills and inspire hope; however, patients often experience hurdles to accessing such care. Among these obstacles are cost, unawareness that programs exist, the COVID-19 pandemic, and other external factors.

Denise Soltow Hershey, PhD, RN, FNP-BC
Latest Article

Improving Glycemic Control in Individuals With Cancer and Diabetes

It is estimated that 8%-18% of all cancer patients will have preexisting diabetes at the time they are diagnosed with cancer.

Dennie V. Jones, Jr, M
Latest Article

Hedgehog Signal Inhibition Hope or Hype?

Once a human malignancy metastasizes, currently available cytotoxic chemotherapy is usually palliative. While conventional chemotherapy regimens are associated with objective tumor regression, this only occurs in a minority of patients.

Dennis Bittner, PhD
Latest Article

Liquid Biopsy Technology Grows More Varied and Potentially More Useful in NSCLC

The definition of liquid biopsy has expanded to include the collection of cell-free DNA (cfDNA), along with various species of cell-free RNA and exosomes, all of which are capable of providing information on the disease status of patients with cancer.

Dennis C. Shrieve, MD, PhD
Latest Article

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.

Dennis D. Hickstein, MD
Latest Article

Primary Radiation Therapy for Myeloid Sarcoma of the Porta Hepatis

Treating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.

denosumab-wins-drug-award
Latest Article

Denosumab Wins Drug Award

At the 6th Annual Scrip Awards, featuring more than 500 representatives from the pharmaceutical industry, Amgen received the Best New Drug award for denosumab, the first approved inhibitor of RANK ligand.

Deukwoo Kwon, PhD
Latest Article

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Devalingam Mahalingam, MD, PhD
Latest Article

Autophagy Modulation May Be a Novel Approach to Treatment of Advanced Cancers

Although prolonged autophagy can result in cancer cell death, recent investigations suggest that therapy-induced autophagy is a reversible response that promotes cancer cell survival, and thus may diminish the efficacy of some therapeutic agents.

Devera Pine
Latest Article

Bone-Targeted Therapies Evolve in Prostate Cancer

The treatment of bone metastases in prostate cancer has changed over the years, and several options are now either available or under development.

Devin C. Flaherty, DO, PhD
Latest Article

Interdisciplinary Tumor Conferences: A Surgical Oncology Fellow's Review and Perspective

Devin C. Flaherty, DO, PhD, a surgical oncology fellow, discusses the evolution of interdisciplinary tumor board conferences and remarks on why they are so beneficial to the care of patients with cancer.

Dhaval Shah, MD
Latest Article

Planning Ahead for a Career

The 3 years of my fellowship training were a life-changing experience that will stay with me forever.

Dialecti Voudouris, MD
Dian Wang, MD
Latest Article

Radiation Therapy, Chemotherapy, Targeted Therapy, and Possibly Immunotherapy in Localized Sarcoma

As clinicians have gained an improved understanding of the biology of soft-tissue sarcoma malignancies, the ability to better distinguish and identify subtypes has extended the hope of targeted treatment options.

Diana Osorio, MD
Latest Article

Providing Oncology Services in Impoverished Countries

Many of us training in the United States have encountered patients and their families from resource-limited regions of the world-families who have uprooted themselves for the chance to save the lives of their children diagnosed with cancer.

Diana Verrilli
Latest Article

Top 3 Must Do's to Prepare for Managed Care in 2016

Although there still are many unknowns, especially in light of this being an election year that will bring a new administration, it’s already very clear how the transition to value is affecting oncology practices.

Diana Verrilli, MS
Latest Article

Moving to Electronic Prior Authorization Requires Incremental Steps

In a time of tremendous technological advancement, how is it that 90% of communications between providers and payers for prior authorizations are still done by phone or fax, and how do we move to more automated processes?1

Diane Corjulo, BSN
Latest Article

Merging Community Practices With an Academic Cancer Center

Consolidation of community oncology practices with hospital-based cancer centers is an accelerating trend that will affect future healthcare delivery models. This year, the Community Oncology Alliance reported hospital acquisitions and corporate mergers among 55% of 1338 community oncology practices surveyed, representing a 20% increase over the previous year's results.

Diane Reidy-Lagunes, MD, MS, MSK
Diane West
Latest Article

Politics & Policy: March 2007

The Politics and Policy page provides a concise and timely round-up of key government-related oncology and biotechnology news. Content is focused upon the public sector activities that are most likely to impact the evolving oncology and biotech industries.

Dianna S. Howard, MD
Latest Article

Marking 25 Years of Progress in Blood and Marrow Transplantation

While major accomplishments in blood and marrow transplantation (BMT) were being made around the country, the first BMT program at Wake Forest Baptist came into view, a vision brought to life by David D. Hurd, MD.

Dietmar Berger, Global Head of Development, Sanofi Sponsored Content by Sanofi
Dimitry Gabrilovitch MD PhD
Latest Article

Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas

Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.

Dipen J. Parekh, MD
Latest Article

Landmark Trial Puts Robotic Surgery to the Test in Bladder Cancer

Vivek Venkatramani, MD, and Dipen J. Parekh, MD, discuss the evolution of surgery in bladder cancer.

Dipti Gupta, MD, MPH, Memorial Sloan Kettering Cancer Center
Dirk Arnold, MD, PhD, Instituto CUF de Oncologia
Dirk Arnold, MD, PhD, KTB Klinik fur Tumorbiologie GmbH & Co. KG
Dirk Arnold, MD, PhD, Tumor Biology Center
Dirk De Ruysscher, MD, PhD, Maastricht University Medical Center
Dirk Schadendorf, MD, PhD, West German Cancer Center at University Hospital Essen